Author: BusinessWire

Interview will air on Thursday, March 11, 2021 at 12:30 pm EST
STAFFORD, Texas–(BUSINESS WIRE)–Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherap…

OAKLAND, Calif.–(BUSINESS WIRE)–#NSAIDs–A California Workers’ Compensation Institute (CWCI) study finds that nonsteroidal anti-inflammatories (NSAIDs) now account for more than a third of all drugs dispensed to injured workers in California, triple …

OAKLAND, Calif.–(BUSINESS WIRE)–#NSAIDs–A California Workers’ Compensation Institute (CWCI) study finds that nonsteroidal anti-inflammatories (NSAIDs) now account for more than a third of all drugs dispensed to injured workers in California, triple …

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) (“Merrimack” or the “Company”) today announced its full year 2020 financial results for the period ended December 31, 2020.

“We are pleased that both Ipsen Pharmaceutica…

BOSTON–(BUSINESS WIRE)–AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, including the commercializat…

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the acceptance of five abstracts for poster presentation at the upcoming A…

WATERTOWN, Mass.–(BUSINESS WIRE)–SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present data on the next generation SQZ™ APCs and the broa…

UTRECHT, The Netherlands & PHILADELPHIA–(BUSINESS WIRE)–LAVA Therapeutics B.V., a biotechnology company focused on applying its expertise in bispecific gamma-delta T cell engagers (bsTCE) to transform cancer therapy, today announced that a poster fea…

CAMBRIDGE, Mass. & BEIJING–(BUSINESS WIRE)–$BGNE #BTKi–BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced multiple presentatio…

– Evidence of biologic activity of GMI-1359 observed in Phase 1b clinical trial interim analysis
– Preclinical data highlight anti-tumor activity in pancreatic cancer model with GMI-1757, a novel galectin-3 antagonist
ROCKVILLE, Md.–(BUSINESS WIRE)–…